key: cord-0020839-bj5fm76t authors: Msaouel, Pavlos; Oromendia, Clara; Siefker-Radtke, Arlene O.; Tannir, Nizar M.; Subudhi, Sumit K.; Gao, Jianjun; Wang, Yinghong; Siddiqui, Bilal A.; Shah, Amishi Y.; Aparicio, Ana M.; Campbell, Matthew T.; Zurita, Amado J.; Shaw, Leah K.; Lopez, Lidia P.; McCord, Heather; Chakraborty, Sandip N.; Perales, Jacqueline; Lu, Cong; Van Alstine, Michael L.; Elashoff, Michael; Logothetis, Christopher title: Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors date: 2021-08-30 journal: JAMA Netw Open DOI: 10.1001/jamanetworkopen.2021.22998 sha: a9756d69540bf0267a21f1bf8ec2756311bdea8a doc_id: 20839 cord_uid: bj5fm76t IMPORTANCE: Immune checkpoint inhibitors can produce distinct toxic effects that require prompt recognition and timely management. OBJECTIVE: To develop a technology-enabled, dynamically adaptive protocol that can provide the accurate information needed to inform specific remedies for immune toxic effects in patients treated with immune checkpoint inhibitors. DESIGN, SETTING, AND PARTICIPANTS: An open-label cohort study was conducted at a single tertiary referral center from September 6, 2019, to September 3, 2020. The median follow-up duration was 63 (interquartile range, 35.5-122) days. Fifty patients with genitourinary cancers treated with immune checkpoint inhibitors were enrolled. INTERVENTIONS: A fit-for-purpose electronic platform was developed to enable active patient and care team participation. A smartphone application downloaded onto patients’ personal mobile devices prompted them to report their symptoms at least 3 times per week. The set of symptoms and associated queries were paired with alert thresholds for symptoms requiring clinical action. MAIN OUTCOMES AND MEASURES: The primary end point of this interim analysis was feasibility, as measured by patient and care team adherence, and lack of increase in care team staffing. Operating characteristics were estimated for each symptom alert and used to dynamically adapt the alert thresholds to ensure sensitivity while reducing unnecessary alerts. RESULTS: Of the 50 patients enrolled, 47 had at least 1 follow-up visit and were included in the analysis. Median age was 65 years (range, 37-86), 39 patients (83%) were men, and 39 patients (83%) had metastatic cancer, with the most common being urothelial cell carcinoma and renal cell carcinoma (22 [47%] patients each). After initial onboarding, no further care team training or additional care team staffing was required. Patients had a median study adherence rate of 74% (interquartile range, 60%-86%) and 73% of automated alerts were reviewed within 3 days by the clinic team. Symptoms with the highest positive predictive value for adverse events requiring acute intervention included dizziness (21%), nausea/vomiting (26%), and shortness of breath (14%). The symptoms most likely to result in unnecessary alerts were arthralgia and myalgia, fatigue, and cough. CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest an acceptable and fiscally sound method can be developed to create a dynamic learning system to detect and manage immune-related toxic effects. completed the embedded algorithm displayed a summary. Patients could also submit symptoms at any point, if desired. If any of the questions met the severity thresholds previously determined, the patient would be prompted to contact their care team with a direct link to phone them. The MDACC clinical trials platform Prometheus was leveraged as the central source of care team notifications for this trial. A dashboard was created to display summaries of patient reports of alertable symptoms, which were also emailed to their care teams in real time (eAppendix C). Care teams were instructed to review and resolve these alerts within The set of symptoms and associated questions that was created to detect upcoming adverse events is included in eAppendix C. A team of clinical experts identified common and/or severe toxicities among this patient group, as well as their corresponding clinical symptoms. Having selected the appropriate symptoms, questions for each were created to capture necessary details to understand when immediate interaction of patients with their care teams was necessary. The PRO-CTCAE 1 provided inspiration but has not been validated for immunotoxicity monitoring nor high-frequency electronic reporting. [2] [3] [4] To achieve high patient compliance, a team inclusive of clinical content experts, statisticians, user experience experts, and designers arrived at a final set of queries to assure efficiency without compromising goals. First, all symptom survey questions were reviewed, language simplified and shortened whenever possible, and parallel structures maintained across questions to aid comprehension. 5 Second, an initial multiple-choice question was created in which patients selected which symptoms they were experiencing. This allowed patients to only answer a small subset of questions, i.e., those relevant to their current state. Uniform and precisely defined symptom queries were central to the study. Symptomatic patients selected from a tailored inventory to inform the care team of toxicity details in a standardized format. The nature and severity of the reported toxicity was used to prompt alerts and recommend consensus remedies (eAppendix D). The initial thresholds for these alerts (eAppendix C) were set based on clinician consensus (e.g., reporting of severe or very severe cough) or a state known to lead to a severe symptom within two weeks (e.g., reporting of fever). This heightened level of granularity and frequency of symptom collection is not often available. Thus, dynamic adaptation of these alert thresholds was planned as described below. To allow for unanticipated patient concerns, provisions were made to encourage patients to write in any additional symptoms in free text form. All text entries triggered an alert for care teams to review, as clinical severity could not be determined in real time. Patient answers and care team responses were collected in real time and monitored weekly by trial staff. Research teams also graded adverse events using CTCAE guidelines 6 via chart review every four to six weeks. A monthly cadence was used to extract dates and details of clinical interventions (defined above). Assignment of interventions to adverse events was manually adjudicated by the principal investigator while blinded to concurrent symptom responses. The goal of the monitoring system was to alert the care team to acute, clinically meaningful toxicities. We defined these adverse events as those with Common Terminology Criteria for Adverse Events (CTCAE) grade of at least 2 and that were associated with a clinical intervention. Clinical interventions were defined as treatment modifications (pause, dose reduction, or termination of immunotherapy, concomitant targeted therapy, or supportive therapy) or new interactions with healthcare providers due to toxicities that developed after treatment initiation, including emergency department visits or hospitalizations. Adverse events within two weeks of an alert were considered temporally linked to that alert. The symptoms included in this study were those judged by the panel of experts, described below, to be of significant concern to warrant alerting care teams and patients for potential intervention. The electronically enabled alerts were considered appropriate when they were followed by a linked intervention as defined above. Although beyond the scope of this initial report, effective alerts were those that led to remedies that mitigated toxicity. Robust analysis of effectiveness, using this definition, requires longer follow-up and will be the subject of a subsequent report. Operating characteristics were estimated for each symptom alert and were conditional on the symptom having been reported. To prevent over-indexing for patients with more alerts, subsequent reports for a patient were downweighted by a factor of 1/k, where k is the number of alerts [for positive predictive value (PPV) and sensitivity] or non-alerts [for negative predictive value (NPV) and specificity] for that symptom for that patient. The formulas used for PPV, NPV, sensitivity, and specificity are listed in eAppendix F. The analysis included stringent requirements for threshold increases to ensure patient safety, reduce risk of overfitting, and account for the fact that a single symptom alert could be triggered by one of several associated questions. Symptoms with a sensitivity smaller than 10% were identified as candidates for an increase in threshold stringency. Within each symptom, questions that had led to alerts in at least five unique patients were considered, with those more commonly alerting studied first. The impact of increasing this initial question's alert threshold by one level was studied by calculating the NPV and sensitivity of the full symptom alert under this counterfactual condition. The change was recommended if the NPV increased and the sensitivity did not decrease (i.e., none of the alerts removed were linked with subsequent adverse events). If this change was found to be beneficial, the subsequent level was considered, as well as the next most common alerting question for that symptom. This procedure continued until a question did not lead to a change, at which point no further questions were considered for that symptom and the analysis proceeded to the next symptom. Recommended changes were then reviewed and approved by clinical experts before implementation. For all potential immune-related adverse events send the following blood tests: • Complete blood count (CBC) with differential, comprehensive metabolic panel The following section includes definitions of toxicity grades using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. In addition, this section contains "triggers" for initiation of management for these toxicities based on "standard" recommendations and our clinical experience. Grade 4: Discontinue ICI; Trigger: if life-threatening symptoms, then hospitalization, start immunosuppressive agents, emergent consult with GI team, and EGD/colonoscopy Hepatitis: Grade 1: Continue ICI; Trigger: if alanine transaminase (ALT) and/or aspartate transaminase (AST) between 1.5 to 3.0x baseline, then continue to monitor closely Grade 2: Hold ICI; Trigger: if ALT and/or AST > 3.0 to 5.0x baseline, then start immunosuppressive agents and urgent consult with GI team Grade 3-4: Discontinue ICI; Trigger: if ALT and/or AST > 5.0x baseline, then hospitalization, start immunosuppressive agents, and emergent consult with GI team Skin: Rash/inflammatory dermatitis: Grade 1: Continue ICI Grade 2: Hold ICI; Trigger: if covers > 10% and ≤ 30% BSA, then urgent consult with dermatology team Bullous dermatoses: Grade 1: ICI administration per treating physician's clinical judgement. Trigger: if blisters cover < 10% BSA, then close monitoring and consult with dermatology team. Grade 2: Hold ICI; Trigger: if blisters cover > 10% and < 30% toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS) (AKA: drug-induced hypersensitivity syndrome or DIHS) Grade 1: N/A Grade 2: N/A Grades 3-4: Discontinue ICI; Trigger: if skin sloughing/mucous membrane detachment, hospitalization Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Choice of a patient-reported outcome measure for patients with anal cancer for use in cancer clinical trials and routine clinical practice: a mixed methods approach Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy -a feasibility study Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy Parallel structure: a source of facilitation in sentence comprehension Common terminology criteria for adverse events : (CTCAE) version 5.0 (Accessed on Hypothyroidism: Grade 1: Continue immune checkpoint inhibitor (ICI) and monitor TSH, free T4 Grade 2: Continue ICI; Trigger: if mildly or moderately symptomatic or TSH > 10, then supplement thyroid hormone and consult endocrinology team Grades 3-4: Hold ICI; Trigger: if severely symptomatic, then hospitalization, supplement thyroid hormone, and urgent consultation with endocrinology team All neuromuscular/joint/cardiac reactions: Grade 1: ICI administration as per clinical judgement of treating physician and consider consulting rheumatology, neurology and/or cardiology teams Grade 2: Hold ICI, consider starting immunosuppressive agents, and urgent consultation with rheumatology, neurology and/or cardiology teams Grades 3-4: Hold ICI, hospitalization, start immunosuppressive agents, and emergent consultation with rheumatology, neurology and/or cardiology teams Colitis: Grade 1: ICI administration as per clinical judgement of treating physician; Trigger: if increase of < 4 stools per day over baseline, then close monitoring and consider consulting GI team Grade 2: Hold ICI; Trigger: if increase of 4 to 6 stools per day over baseline, then start immunosuppressive agents, consult with GI team, and esophagogastroduodenoscopy (EGD)/colonoscopy Pneumonitis: Grade 1: Hold ICI; Trigger: if asymptomatic or mildly symptomatic, then consult pulmonary team and work up to rule out alternate causes. Grades 2-4: Discontinue ICI; Trigger: if symptomatic, then hospitalization, start immunosuppressive agents and urgent consult with pulmonary team. Nephritis: Grade 1 (creatinine increased up to 1.5x of baseline): Continue ICI and repeat creatinine levels in 3 to 7 days; Trigger: if continued increase in creatinine, then order kidney biopsy even in setting of no urine white blood cells or red blood cells. Grade 2 (creatinine increased 1.5x to 3x of baseline): Hold ICI, start immunosuppressive agents, and urgent consult with renal team, with kidney biopsy to be performed within 3 days of immunosuppressive agent initiation even in setting of bland urine. Grade 3 (creatinine increased > 3x of baseline) and grade 4 (creatinine increased > 6x of baseline): Hold ICI and assess for dialysis indications (hyperkalemia, azotemia, acidosis, decreased urine output, volume overload); start immunosuppressive agents and urgent consult with renal team, with kidney biopsy to be performed within 3 days of immunosuppressive agent initiation even in setting of bland urine.Spoke to patient. The patient still reports nausea and loss of appetite. The patient is still not feeling well but was able to eat a little better. The patient had two episodes of loose stools. The patient's lab results were received today and emailed to the treating oncologist. The patient will be evaluated by their local oncologist. The patient states they will report any new symptoms.---------------Reviewed proper storage of research meds until research team can meet face to face to collect medication. Patient will e-mail me research med diary.